0001209191-21-012547.txt : 20210219
0001209191-21-012547.hdr.sgml : 20210219
20210219191108
ACCESSION NUMBER: 0001209191-21-012547
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210217
FILED AS OF DATE: 20210219
DATE AS OF CHANGE: 20210219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: APPLE ROBERT F
CENTRAL INDEX KEY: 0001054942
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32302
FILM NUMBER: 21657772
MAIL ADDRESS:
STREET 1: C/O INKLINE PHARMACEUTICAL CO INC
STREET 2: SENTRY PARK EAST 1720 WALTON ROAD
CITY: BLUE BELL
STATE: PA
ZIP: 19422
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANTARES PHARMA, INC.
CENTRAL INDEX KEY: 0001016169
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 411350192
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 PRINCETON SOUTH
STREET 2: SUITE 300
CITY: EWING
STATE: NJ
ZIP: 08628
BUSINESS PHONE: 609-359-3020
MAIL ADDRESS:
STREET 1: 100 PRINCETON SOUTH
STREET 2: SUITE 300
CITY: EWING
STATE: NJ
ZIP: 08628
FORMER COMPANY:
FORMER CONFORMED NAME: ANTARES PHARMA INC
DATE OF NAME CHANGE: 20060120
FORMER COMPANY:
FORMER CONFORMED NAME: ANTARES PHARMA INC
DATE OF NAME CHANGE: 20020520
FORMER COMPANY:
FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/
DATE OF NAME CHANGE: 20010604
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-17
0
0001016169
ANTARES PHARMA, INC.
ATRS
0001054942
APPLE ROBERT F
C/O ANTARES PHARMA, INC.
100 PRINCETON SOUTH, SUITE 300
EWING
NJ
08628
1
1
0
0
President & CEO
Common Stock
2021-02-17
4
A
0
267878
0.00
A
2563033
D
Common Stock
2021-02-17
4
F
0
116313
4.73
D
2446720
D
Common Stock
2021-02-17
4
M
0
5519
2.62
A
2452239
D
Common Stock
2021-02-17
4
S
0
5519
4.75
D
2446720
D
Common Stock
2021-02-18
4
M
0
250000
0.88
A
2696720
D
Common Stock
2021-02-18
4
S
0
232156
5.00
D
2464564
D
Common Stock
2021-02-18
4
S
0
17844
5.01
D
2446720
D
Common Stock
2021-02-18
4
S
0
241960
5.00
D
2204760
D
Stock Option (right to buy)
2.62
2021-02-17
4
M
0
5519
0.00
D
2025-03-09
Common Stock
5519
0
D
Stock Option (right to buy)
0.88
2021-02-18
4
M
0
250000
0.00
D
2026-03-09
Common Stock
250000
0
D
On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold.
This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.
This sale of common stock was effected pursuant to a Rule 10b5-1 trading plan.
The options vested in equal quarterly installments over one year from the grant date of March 10, 2015.
The options vested in equal quarterly installments over three years from the grant date of March 10, 2016.
/s/Keith Muckenhirn as attorney-in-fact for Robert F. Apple
2021-02-19